Serum Insulin PP after 75gm Glucose load

Diabetes

Report in 4Hrs

At Home

Fasting Required

Details

Assesses insulin levels in blood; used in diagnosing insulin resistance and metabolic syndrome.

₹229₹770

70% OFF

Serum Insulin PP after 75gm Glucose load - Comprehensive Medical Test Guide

Section 1: Why is it done?
- Test Purpose: Measures serum insulin levels 2 hours after administering a 75-gram oral glucose load to evaluate pancreatic beta-cell function and insulin secretion response to glucose stimulation.
- Primary Indications: Assessment of insulin resistance and beta-cell dysfunction in patients with suspected diabetes mellitus or impaired glucose tolerance
- Common Clinical Reasons: Screening for type 2 diabetes, evaluation of hyperglycemia, assessment of metabolic syndrome, investigation of hypoglycemia etiology, monitoring prediabetic patients, and evaluating insulin secretion capacity
- Timing of Test: Performed during oral glucose tolerance testing (OGTT); blood sample collected exactly 2 hours after consuming 75 grams of glucose solution
- Clinical Circumstances: During routine screening in at-risk populations, evaluation of gestational diabetes in pregnant women, assessment of family history of diabetes, or investigation of unexplained glucose abnormalities
Section 2: Normal Range
- Normal Reference Range: <12 mIU/mL or <84 pmol/L for fasting insulin; PP (postprandial) insulin typically <16 mIU/mL at 2 hours
- Alternative Units: Results may be expressed in mIU/mL (milliunits per milliliter) or pmol/L (picomoles per liter); conversion factor: 1 mIU/mL = 7.04 pmol/L
- Borderline Values: 12-16 mIU/mL indicates mild elevation; may suggest early insulin resistance or impaired glucose tolerance
- Elevated Values: >16 mIU/mL indicates hyperinsulinemia; reflects increased insulin demand to maintain glucose homeostasis
- Low Values: <2 mIU/mL may indicate pancreatic insufficiency or type 1 diabetes with reduced beta-cell function
- Laboratory Variation: Reference ranges may vary slightly between laboratories; always interpret results in context of specific laboratory's reference intervals
Section 3: Interpretation
- Normal Results (<12 mIU/mL): Indicates appropriate beta-cell function with adequate insulin secretion in response to glucose challenge; normal glucose tolerance and no evidence of insulin resistance
- Elevated Insulin (>16 mIU/mL): Suggests insulin resistance where pancreatic cells must produce more insulin to maintain normal glucose levels; commonly associated with metabolic syndrome, polycystic ovary syndrome, or prediabetes
- Markedly Elevated (>25 mIU/mL): Indicates significant insulin resistance and heightened risk for type 2 diabetes development; may reflect established metabolic dysfunction
- Inappropriately Low Insulin: Despite elevated glucose levels, suggests beta-cell failure or dysfunction; characteristic of type 1 diabetes or advanced type 2 diabetes with beta-cell exhaustion
- HOMA-IR Index Calculation: PP insulin used with fasting glucose to calculate Homeostasis Model Assessment for Insulin Resistance (HOMA-IR); values >2.5 suggest significant insulin resistance
- Clinical Context Importance: Results must be interpreted alongside glucose levels, BMI, blood pressure, lipid profile, and clinical presentation; isolated insulin elevation requires correlation with glucose tolerance status
- Factors Affecting Results: Stress, physical activity, medications (corticosteroids, beta-blockers), menstrual cycle, infections, obesity, liver disease, and certain hormonal conditions can influence postprandial insulin levels
Section 4: Associated Organs
- Primary Organ - Pancreas: Beta-cells in islets of Langerhans produce insulin in response to glucose; this test directly evaluates pancreatic endocrine function and insulin secretion capacity
- Secondary Target - Liver: Hepatic insulin resistance is major contributor to systemic glucose intolerance; fatty liver disease associated with impaired insulin signaling and elevated postprandial insulin
- Target Tissues - Skeletal Muscle and Adipose: Primary sites of insulin action for glucose uptake; insulin resistance in these tissues drives compensatory hyperinsulinemia reflected in elevated PP insulin levels
- Regulatory Organs - Brain and Gut: Hypothalamus regulates glucose homeostasis; incretin hormones from GI tract influence insulin secretion; dysfunction in these systems contributes to abnormal glucose and insulin responses
- Associated Diseases - Type 2 Diabetes: Early stages show elevated PP insulin with elevated glucose (impaired fasting glucose/impaired glucose tolerance); late stages show low insulin with high glucose (beta-cell exhaustion)
- Associated Diseases - Metabolic Syndrome: Characterized by elevated PP insulin with central obesity, hypertension, dyslipidemia, and impaired glucose tolerance; increased risk of cardiovascular disease and diabetes
- Associated Conditions - PCOS: Polycystic ovary syndrome often associated with insulin resistance and elevated PP insulin; contributes to androgen excess, fertility problems, and metabolic dysfunction
- Associated Conditions - Gestational Diabetes: Elevated PP insulin in pregnancy increases risk of adverse maternal and fetal outcomes; strong predictor of future type 2 diabetes in mother and metabolic dysfunction in offspring
- Complications Associated with Hyperinsulinemia: Increased cardiovascular risk, atherosclerosis, hypertension, dyslipidemia, increased inflammation, higher cancer risk, and accelerated aging of multiple organ systems
Section 5: Follow-up Tests
- 2-Hour Postprandial Glucose: Measured simultaneously with insulin PP; if glucose >140 mg/dL, indicates impaired glucose tolerance; combined with insulin helps assess degree of glucose dysregulation
- Fasting Glucose and Insulin: Used to calculate HOMA-IR index for quantifying insulin resistance; fasting values provide baseline assessment of glucose and insulin when not stimulated
- Hemoglobin A1C (HbA1c): Assesses average blood glucose over 2-3 months; recommended as confirmatory test for diabetes diagnosis; important for monitoring glycemic control in diabetic patients
- Lipid Panel: Essential follow-up as insulin resistance often associated with dyslipidemia (elevated triglycerides, low HDL); dyslipidemias increase cardiovascular risk substantially
- C-Peptide Level: Reflects endogenous insulin secretion independent of exogenous insulin; useful in patients already on insulin therapy to assess residual beta-cell function
- Adiponectin and Inflammatory Markers: Elevated inflammatory markers (CRP, TNF-alpha) and low adiponectin correlate with insulin resistance; additional assessment of metabolic dysfunction
- Liver Function Tests: Elevated ALT/AST suggest fatty liver disease (NAFLD) commonly associated with insulin resistance; hepatic steatosis contributes to impaired insulin signaling
- Kidney Function Tests: Creatinine, eGFR, and urine albumin-creatinine ratio assess for diabetic complications; early albuminuria indicates microvascular damage and increased cardiovascular risk
- Thyroid Function Tests: Hypothyroidism associated with insulin resistance and metabolic dysfunction; thyroid autoimmunity commonly coexists with type 1 diabetes and autoimmune disease
- Androgen Profile (in women): Elevated insulin drives androgen excess in PCOS; measurement of testosterone and DHEA-S helps diagnose hormonal abnormalities associated with insulin resistance
- Imaging Studies: Abdominal ultrasound or CT to assess fatty liver; DEXA scan to evaluate body composition; coronary artery calcium scoring in high-risk patients with severe insulin resistance
- Monitoring Frequency: Annual screening in at-risk populations; more frequent (every 3-6 months) in patients with prediabetes or established glucose intolerance; intensified monitoring in pregnancy
Section 6: Fasting Required?
- Fasting Requirement: YES - Fasting is required for this test as part of the standard Oral Glucose Tolerance Test (OGTT) protocol
- Fasting Duration: 8-10 hours overnight fast required before test commencement; typically begin test between 6-8 AM after fasting from previous evening dinner
- Pre-Test Instructions: Nothing to eat or drink except water during fasting period; no chewing gum, mints, or candy allowed; water consumption permitted and encouraged
- Medication Management: Continue regular medications unless specifically instructed otherwise by physician; discuss with healthcare provider if on diabetes medications, corticosteroids, or other drugs affecting glucose metabolism
- Physical Activity: Avoid strenuous exercise for 24 hours before test; moderate activity permitted but extreme exertion can affect glucose and insulin values
- Stress Management: Minimize stress on test day as acute stress elevates cortisol and can increase glucose and insulin levels; arrive early to allow 10-15 minutes rest before testing
- Dietary Considerations: Maintain normal diet 3 days before test (no fasting diet or carbohydrate restriction beforehand); severe dietary restriction can artificially alter glucose tolerance results
- Timing of Glucose Administration: After baseline fasting blood draw, patient consumes exactly 75 grams of glucose solution within 5 minutes; the PP insulin is drawn exactly 120 minutes (2 hours) after glucose consumption
- Special Populations: Pregnant women should continue normal food intake before glucose loading; patients with severe nausea/vomiting may need alternative test timing; inform laboratory of pregnancy status
- Documentation: Inform laboratory of all medications, supplements, recent illnesses, or menstrual status; these factors documented as they may influence interpretation of results

How our test process works!